Stoke Therapeutics (NASDAQ:STOK) Given “Buy” Rating at HC Wainwright

HC Wainwright restated their buy rating on shares of Stoke Therapeutics (NASDAQ:STOK) in a research note issued to investors on Wednesday morning, Benzinga reports. They currently have a $35.00 price objective on the stock.

Several other equities research analysts also recently weighed in on STOK. Leerink Partnrs raised Stoke Therapeutics to a “strong-buy” rating in a research report on Friday, October 11th. Wedbush reissued an “outperform” rating and set a $17.00 price target on shares of Stoke Therapeutics in a research report on Thursday, July 11th. Needham & Company LLC reaffirmed a “buy” rating and issued a $22.00 price objective on shares of Stoke Therapeutics in a research report on Thursday, August 8th. Finally, Leerink Partners assumed coverage on shares of Stoke Therapeutics in a research report on Monday, October 14th. They set an “outperform” rating and a $18.00 target price on the stock. One analyst has rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, Stoke Therapeutics has an average rating of “Buy” and an average price target of $20.83.

Stoke Therapeutics Stock Up 1.5 %

Shares of STOK stock opened at $13.25 on Wednesday. Stoke Therapeutics has a fifty-two week low of $3.77 and a fifty-two week high of $17.58. The firm’s 50 day moving average price is $13.24 and its two-hundred day moving average price is $13.70. The stock has a market cap of $697.59 million, a price-to-earnings ratio of -6.08 and a beta of 0.95.

Stoke Therapeutics (NASDAQ:STOK) last posted its earnings results on Wednesday, August 7th. The company reported ($0.46) earnings per share for the quarter, beating the consensus estimate of ($0.57) by $0.11. Stoke Therapeutics had a negative net margin of 683.35% and a negative return on equity of 57.89%. The business had revenue of $4.83 million for the quarter, compared to analyst estimates of $3.33 million. On average, equities analysts forecast that Stoke Therapeutics will post -2.1 EPS for the current fiscal year.

Insider Transactions at Stoke Therapeutics

In related news, major shareholder Skorpios Trust sold 1,937,500 shares of Stoke Therapeutics stock in a transaction on Thursday, September 19th. The shares were sold at an average price of $14.05, for a total value of $27,221,875.00. Following the completion of the sale, the insider now owns 8,906,181 shares in the company, valued at approximately $125,131,843.05. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 11.30% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the stock. Los Angeles Capital Management LLC lifted its position in shares of Stoke Therapeutics by 54.3% during the third quarter. Los Angeles Capital Management LLC now owns 103,005 shares of the company’s stock worth $1,266,000 after purchasing an additional 36,240 shares during the last quarter. Mesirow Financial Investment Management Inc. bought a new position in Stoke Therapeutics during the 3rd quarter worth approximately $192,000. Healthcare of Ontario Pension Plan Trust Fund lifted its holdings in Stoke Therapeutics by 426.1% during the 2nd quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 1,387,200 shares of the company’s stock worth $18,741,000 after buying an additional 1,123,500 shares during the last quarter. Lynx1 Capital Management LP grew its position in shares of Stoke Therapeutics by 40.3% in the 2nd quarter. Lynx1 Capital Management LP now owns 5,185,191 shares of the company’s stock worth $70,052,000 after acquiring an additional 1,488,371 shares in the last quarter. Finally, The Manufacturers Life Insurance Company increased its holdings in shares of Stoke Therapeutics by 16.7% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 13,964 shares of the company’s stock valued at $189,000 after acquiring an additional 1,994 shares during the last quarter.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.